TYSONS CORNER, VA, Oct. 10, 2016 — Engility (NYSE: EGL) will conduct clinical trials to test the efficacy of experimental Chikungunya virus vaccines under a five-year, $10 million task order from the Walter Reed Army Institute of Research, ExecutiveBiz reported Friday.
The company said Thursday the new work comes under the potential $900 million U.S. Army medical product research-and-development contract Engility won a position on early this year.
“With this contract, our Engility medical experts will work side-by-side with the researchers at the Walter Reed Institute to fight Chikungunya and protect our men and women in uniform and all of those vulnerable to this virus, ” said Engility CEO Lynn Dugle.
About Executive Mosaic: Founded in 2002, Executive Mosaic is a leadership organization and media company. It provides its members an opportunity to learn from peer business executives and government thought leaders while providing an interactive forum to develop key business and partnering relationships. Executive Mosaic offers highly coveted executive events, breaking business news on the Government Contracting industry, and delivers robust and reliable content through seven influential websites and four consequential E-newswires. Executive Mosaic is headquartered in Tysons Corner, VA. www.executivemosaic.com
Contact:
David Smith
(703) 226-7002
david.smith@executivemosaic.com
